Oxymorphazone: A long-acting opiate analgesic

Geoffrey Ling, Steven Galetta, Gavril W. Pasternak

Research output: Contribution to journalArticle

Abstract

1. Treating rat brain homogenates in vitro with oxymorphazone, the hydrazone derivative of oxymorphone, selectively inhibited in a long-acting manner the highaffinity (mu1) binding of a number of3H-opioids. This inhibition was not affected by extensive wash procedures which did effectively reverse classical opiates such as morphine and naloxone. 2. A similar, persistent inhibition of binding was observed following in vivo administration of the drug. Both systemically and intracerebroventicularly, oxymorphazone produced a dose-dependent analgesia. 3. Acutely, oxymorphazone (ED50, 0.6 mg/kg, sc) was approximately half as potent as oxymorphone (ED50, 0.3 mg/kg, sc) in the tail-flick assay. 4. Administered at their ED50 doses, both compounds had the same durations of action. As the doses of drug were increased, however, the time course of oxymorphazone's analgesia became far more prolonged than that of oxymorphone. 5. Following the administration of oxymorphazone (100 mg/kg), over 50% of the mice remained analgesic for greater than 24 hr, as opposed to none of the mice given oxymorphone (100 mg/kg). 6. Oxymorphazone was far more potent intraventricularly (icv) than systemically. Fifty percent of the mice remained analgesic for greater than 20 hr following the injection of 40 μg/mouse (icv), whereas no mice remained analgesic after 20 hr following doses of oxymorphone as high as 50 μg/mouse (icv). 7. These long-lasting analgesic actions of oxymorphazone could not be easily explained on pharmacokinetic grounds. Repeated administration of oxymorphazone daily for 3 days resulted in significant tolerance.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalCellular and Molecular Neurobiology
Volume4
Issue number1
DOIs
StatePublished - Mar 1 1984
Externally publishedYes

Fingerprint

Opiate Alkaloids
Analgesics
Oxymorphone
Analgesia
oxymorphazone
Naloxone
Pharmaceutical Preparations
Morphine
Opioid Analgesics
Tail

Keywords

  • analgesia
  • mu binding site
  • naloxone
  • opiate
  • opiate receptor
  • oxymorphazone

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Oxymorphazone : A long-acting opiate analgesic. / Ling, Geoffrey; Galetta, Steven; Pasternak, Gavril W.

In: Cellular and Molecular Neurobiology, Vol. 4, No. 1, 01.03.1984, p. 1-13.

Research output: Contribution to journalArticle

Ling, Geoffrey ; Galetta, Steven ; Pasternak, Gavril W. / Oxymorphazone : A long-acting opiate analgesic. In: Cellular and Molecular Neurobiology. 1984 ; Vol. 4, No. 1. pp. 1-13.
@article{e500829e1ee44431acfca1f4632b749e,
title = "Oxymorphazone: A long-acting opiate analgesic",
abstract = "1. Treating rat brain homogenates in vitro with oxymorphazone, the hydrazone derivative of oxymorphone, selectively inhibited in a long-acting manner the highaffinity (mu1) binding of a number of3H-opioids. This inhibition was not affected by extensive wash procedures which did effectively reverse classical opiates such as morphine and naloxone. 2. A similar, persistent inhibition of binding was observed following in vivo administration of the drug. Both systemically and intracerebroventicularly, oxymorphazone produced a dose-dependent analgesia. 3. Acutely, oxymorphazone (ED50, 0.6 mg/kg, sc) was approximately half as potent as oxymorphone (ED50, 0.3 mg/kg, sc) in the tail-flick assay. 4. Administered at their ED50 doses, both compounds had the same durations of action. As the doses of drug were increased, however, the time course of oxymorphazone's analgesia became far more prolonged than that of oxymorphone. 5. Following the administration of oxymorphazone (100 mg/kg), over 50{\%} of the mice remained analgesic for greater than 24 hr, as opposed to none of the mice given oxymorphone (100 mg/kg). 6. Oxymorphazone was far more potent intraventricularly (icv) than systemically. Fifty percent of the mice remained analgesic for greater than 20 hr following the injection of 40 μg/mouse (icv), whereas no mice remained analgesic after 20 hr following doses of oxymorphone as high as 50 μg/mouse (icv). 7. These long-lasting analgesic actions of oxymorphazone could not be easily explained on pharmacokinetic grounds. Repeated administration of oxymorphazone daily for 3 days resulted in significant tolerance.",
keywords = "analgesia, mu binding site, naloxone, opiate, opiate receptor, oxymorphazone",
author = "Geoffrey Ling and Steven Galetta and Pasternak, {Gavril W.}",
year = "1984",
month = "3",
day = "1",
doi = "10.1007/BF00710938",
language = "English (US)",
volume = "4",
pages = "1--13",
journal = "Cellular and Molecular Neurobiology",
issn = "0272-4340",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Oxymorphazone

T2 - A long-acting opiate analgesic

AU - Ling, Geoffrey

AU - Galetta, Steven

AU - Pasternak, Gavril W.

PY - 1984/3/1

Y1 - 1984/3/1

N2 - 1. Treating rat brain homogenates in vitro with oxymorphazone, the hydrazone derivative of oxymorphone, selectively inhibited in a long-acting manner the highaffinity (mu1) binding of a number of3H-opioids. This inhibition was not affected by extensive wash procedures which did effectively reverse classical opiates such as morphine and naloxone. 2. A similar, persistent inhibition of binding was observed following in vivo administration of the drug. Both systemically and intracerebroventicularly, oxymorphazone produced a dose-dependent analgesia. 3. Acutely, oxymorphazone (ED50, 0.6 mg/kg, sc) was approximately half as potent as oxymorphone (ED50, 0.3 mg/kg, sc) in the tail-flick assay. 4. Administered at their ED50 doses, both compounds had the same durations of action. As the doses of drug were increased, however, the time course of oxymorphazone's analgesia became far more prolonged than that of oxymorphone. 5. Following the administration of oxymorphazone (100 mg/kg), over 50% of the mice remained analgesic for greater than 24 hr, as opposed to none of the mice given oxymorphone (100 mg/kg). 6. Oxymorphazone was far more potent intraventricularly (icv) than systemically. Fifty percent of the mice remained analgesic for greater than 20 hr following the injection of 40 μg/mouse (icv), whereas no mice remained analgesic after 20 hr following doses of oxymorphone as high as 50 μg/mouse (icv). 7. These long-lasting analgesic actions of oxymorphazone could not be easily explained on pharmacokinetic grounds. Repeated administration of oxymorphazone daily for 3 days resulted in significant tolerance.

AB - 1. Treating rat brain homogenates in vitro with oxymorphazone, the hydrazone derivative of oxymorphone, selectively inhibited in a long-acting manner the highaffinity (mu1) binding of a number of3H-opioids. This inhibition was not affected by extensive wash procedures which did effectively reverse classical opiates such as morphine and naloxone. 2. A similar, persistent inhibition of binding was observed following in vivo administration of the drug. Both systemically and intracerebroventicularly, oxymorphazone produced a dose-dependent analgesia. 3. Acutely, oxymorphazone (ED50, 0.6 mg/kg, sc) was approximately half as potent as oxymorphone (ED50, 0.3 mg/kg, sc) in the tail-flick assay. 4. Administered at their ED50 doses, both compounds had the same durations of action. As the doses of drug were increased, however, the time course of oxymorphazone's analgesia became far more prolonged than that of oxymorphone. 5. Following the administration of oxymorphazone (100 mg/kg), over 50% of the mice remained analgesic for greater than 24 hr, as opposed to none of the mice given oxymorphone (100 mg/kg). 6. Oxymorphazone was far more potent intraventricularly (icv) than systemically. Fifty percent of the mice remained analgesic for greater than 20 hr following the injection of 40 μg/mouse (icv), whereas no mice remained analgesic after 20 hr following doses of oxymorphone as high as 50 μg/mouse (icv). 7. These long-lasting analgesic actions of oxymorphazone could not be easily explained on pharmacokinetic grounds. Repeated administration of oxymorphazone daily for 3 days resulted in significant tolerance.

KW - analgesia

KW - mu binding site

KW - naloxone

KW - opiate

KW - opiate receptor

KW - oxymorphazone

UR - http://www.scopus.com/inward/record.url?scp=0021592944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021592944&partnerID=8YFLogxK

U2 - 10.1007/BF00710938

DO - 10.1007/BF00710938

M3 - Article

C2 - 6204757

AN - SCOPUS:0021592944

VL - 4

SP - 1

EP - 13

JO - Cellular and Molecular Neurobiology

JF - Cellular and Molecular Neurobiology

SN - 0272-4340

IS - 1

ER -